利福平治疗妊娠重度肝内胆汁淤积症
Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy.
作者信息
Geenes Victoria, Chambers Jenny, Khurana Rshmi, Shemer Elisabeth Wikstrom, Sia Winnie, Mandair Dalvinder, Elias Elwyn, Marschall Hanns-Ulrich, Hague William, Williamson Catherine
机构信息
Women's Health Academic Centre, King's College London, London, United Kingdom.
Women's Health Research Centre, Imperial College London, London, United Kingdom.
出版信息
Eur J Obstet Gynecol Reprod Biol. 2015 Jun;189:59-63. doi: 10.1016/j.ejogrb.2015.03.020. Epub 2015 Mar 28.
OBJECTIVE
To describe the use of combined ursodeoxycholic acid (UDCA) and rifampicin treatment in intrahepatic cholestasis of pregnancy (ICP).
STUDY DESIGN
A questionnaire survey of 27 women with 28 affected pregnancies identified via the UK and International Obstetric Medicine forum. The clinical case notes of women with ICP treated with combined UDCA and rifampicin therapy were reviewed, and data regarding maternal and perinatal outcomes extracted.
RESULTS
Serum bile acids remained high whilst taking UDCA as monotherapy. In 14 pregnancies (54%) serum bile acids decreased following the introduction of rifampicin. In 10 pregnancies (38%), there was a 50% reduction in serum bile acids. There were no adverse effects reported with either drug.
CONCLUSIONS
This is the first report of the use of rifampicin in ICP. The data suggest that combined treatment with UDCA and rifampicin is an effective way of treating women with severe ICP who do not respond to treatment with UDCA alone.
目的
描述熊去氧胆酸（UDCA）与利福平联合治疗妊娠肝内胆汁淤积症（ICP）的应用情况。
研究设计
通过英国和国际产科医学论坛，对27名患有28例受影响妊娠的女性进行问卷调查。回顾了接受UDCA与利福平联合治疗的ICP女性的临床病例记录，并提取了有关孕产妇和围产期结局的数据。
结果
单独使用UDCA治疗时，血清胆汁酸水平仍居高不下。在14例妊娠（54%）中，引入利福平后血清胆汁酸水平下降。在10例妊娠（38%）中，血清胆汁酸水平降低了50%。两种药物均未报告有不良反应。
结论
这是利福平用于ICP治疗的首次报告。数据表明，UDCA与利福平联合治疗是治疗对单独使用UDCA无反应的重度ICP女性的有效方法。
Zotero 插件